Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

(TheNewswire)

Kelowna, British Columbia – August27, 2025 – TheNewswire -Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW)(the “Company” or “Lexaria”), a global innovator in drugdelivery platforms, today announced that it will participate in the 27th Annual H.C.Wainwright Global Investment Conference, taking place September8ththrough September 10th, 2025.

Richard Christopher, Chief Executive Officer of LexariaBioscience, will deliver a company presentation and be available forone-on-one investor meetings throughout the event. His presentationwill be available for remote viewing anytime after 7:00 AM EST onSeptember 5th at this provided
link.

Event Details:

· Conference:  27th Annual H.C.Wainwright Global Investment Conference

· Date: September 8-10th, 2025

Investors interested in scheduling a meeting with theLexaria management team should contact their H.C. Wainwrightrepresentative or send an email to:  meetings@hcwco.com

About Lexaria Bioscience Corp. &DehydraTECH

DehydraTECH™ is Lexaria’s patented drug deliveryformulation and processing platform technology which improves the waya wide variety of drugs enter the bloodstream, always through oraldelivery.  DehydraTECH has repeatedly evidenced the ability toincrease bio-absorption, reduce side-effects, and deliver some drugsmore effectively across the blood brain barrier. Lexaria operates alicensed in-house research laboratory and holds a robust intellectualproperty portfolio with 50 patents granted and additional patentspending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKINGSTATEMENTS

This press release includes forward-looking statements.Statements as such term is defined under applicable securities laws.These statements may be identified by words such as"anticipate," "if," "believe,""plan," "estimate," "expect,""intend," "may," "could,""should," "will," and other similar expressions.Such forward-looking statements in this press release include, but arenot limited to, statements by the Company relating to the Company’sability to carry out research initiatives, receive regulatoryapprovals or grants or experience positive effects or results from anyresearch or study. Such forward-looking statements are estimatesreflecting the Company's best judgment based upon currentinformation and involve a number of risks and uncertainties, and therecan be no assurance that the Company will actually achieve the plans,intentions, or expectations disclosed in these forward-lookingstatements.  As such, you should not place undue reliance on theseforward-looking statements.  Factors which could cause actual resultsto differ materially from those estimated by the Company include, butare not limited to, government regulation and regulatory approvals,managing and maintaining growth, the effect of adverse publicity,litigation, competition, scientific discovery, the patent applicationand approval process, potential adverse effects arising from thetesting or use of products utilizing the DehydraTECH technology, theCompany’s ability to maintain existing collaborations and realizethe benefits thereof, delays or cancellations of planned R&D thatcould occur related to pandemics or for other reasons, and otherfactors which may be identified from time to time in theCompany's public announcements and periodic filings with the USSecurities and Exchange Commission on EDGAR. The Company provideslinks to third-party websites only as a courtesy to readers anddisclaims any responsibility for the thoroughness, accuracy ortimeliness of information at third-party websites. There is noassurance that any of Lexaria’s postulated uses, benefits, oradvantages for the patented and patent-pending technology will in factbe realized in any manner or in any part. No statement herein has beenevaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat,cure or prevent any disease. Any forward-looking statements containedin this release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update anyforward-looking statements or links to third-party websites containedherein, whether as a result of any new information, future events,changed circumstances or otherwise, except as otherwise required bylaw.

INVESTOR CONTACT:

George Jurcic - Head of InvestorRelations

ir@lexariabioscience.com

Phone: 250-765-6424, ext
202

Copyright (c) 2025 TheNewswire - All rights reserved.